The Pharmacy Times® Gastrointestinal resource center provides news and articles centered around the FDA approved drugs in gastroenterology, as well as links to condition-specific resources, and videos and other content.
What can we help you find?
Despite presenting in only 18% of cases, 16% of all COVID-19 patients only present with gastrointestinal symptoms.
The FDA granted breakthrough therapy designation to dupilumab in September 2020, for the treatment of patients age 12 years and older with eosinophilic esophagitis.
Educate patients about the appropriate and safe use of gastrointestinal products and direct them to seek further medical care when warranted.
Like diabetes, Inflammatory bowel disease may also be linked to a high-fructose diet.
Pharmacists can play an integral role in collaborating with physicians to manage patient therapy.
Nizatidine Oral Solution is a prescription oral product used for the short-term treatment and maintenance therapy of ulcers and for the treatment of esophagitis and associated heartburn due to GERD.
Irritable bowel disease, such as ulcerative colitis and Crohn disease, can increase the risk of both cancer and death.
According to a study published in Genome Medicine, the disruption of gut bacteria through the use of antibiotics soon after birth has the ability to affect the immune system’s process of maturation.
A variety of OTC products, such as antacids, histamine H2 receptor antagonists (H2RAs), and proton pump inhibitors (PPIs), are available to help manage symptoms of gastroesophageal reflux disease (GERD).
Mylan plans to launch adalimumab-fkjp in the United States in July 2023.
According to an online survey of more than 53,000 Americans using PPIs, once or twice daily use significantly increases the likelihood of a positive test for COVID-19.
According to a recent study published in Gut, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn disease, is associated with a more than doubled likelihood of developing dementia.